Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.
Systemic lupus erythematosus, also called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and/or other organs of the body. The most common symptoms include skin rashes and arthritis, often accompanied by fatigue and fever. Lupus occurs mostly in women, typically developing in individuals in their twenties and thirties - prime child-bearing age.
Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with lupus, and these treatments have been shown to improve patient outcomes by reducing disease activity, joint and organ damage, and death. Researchers from The University of California and Brigham and Women's Hospital in Boston recently examined adherence to these medications in a nationwide study of Medicaid beneficiaries with lupus.
"This study is important because it is the first time we have national data about a very vulnerable group of patients, Medicaid beneficiaries with lupus, and our study paints a sobering picture of medication adherence in this group of patients" explains Jinoos Yazdany, MD, MPH; associate clinical director, Lupus Clinic, University of California, San Francisco Medical Center; and lead investigator in the study.
Dr. Yazdany's team reviewed Medicaid records of lupus patients who had received either an immunosuppressive — e.g., oral cyclophosphamide (Cytoxan®) mycophenolate mofetil (CellCept®) or leflunomide (Arava®), methotrexate (Trexall®; Rheumatrex®), or tacrolimus (Prograf®) — or an anti- malarial — e.g., hydroxychloroquine (Plaquenil®) — drug through an outpatient pharmacy between the years of 2000 and 2006. The researchers used pharmacy claims to assess adherence to these treatments by noting the amount of medication dispensed over a six-month period following the initial prescription.
"We observed each patient over a fixed interval of 180 days to ensure all patients were studied for the same time period," explains Dr. Yazdany, whose team also took sociodemographic characteristics and geographic region into consideration when looking at adherence. Additionally, Dr. Yazdany's team made a point to examine the number of patients considered at least 80 percent adherent to their treatment plans.
"Adherence was very low for all drugs. We were surprised to find that less than one in three patients were adherent to most of the drugs we examined. What clinicians need to realize is that a majority of this vulnerable population is not taking their lupus medication as prescribed, putting them at risk for poor health outcomes," says Dr. Yazdany.